Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial Phase III Blind, Parallel Group to Analyze Differences in the Safety of Roflumilast Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily

NCT01849341 is registered in ClinicalTrials.gov with Fundación Pública Andaluza Progreso y Salud as lead sponsor.

NCT NCT01849341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01849341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial Phase III Blind, Parallel Group to Analyze Differences in the Safety of Roflumilast Administered Once a Day on Alternate Days for Two Weeks Compared to the Usual Dosage Once Daily
Lead sponsor
Fundación Pública Andaluza Progreso y Salud
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2012
Completion date
July 31, 2014
Enrollment
105 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)